Abortion Pill Mifepristone Has Its Day(s) In Court

<p><em>Health Affairs</em>' Leslie Erdelack and Jessica Bylander discuss the large amount of news and controversy over the abortion pill mifepristone as the drug's 2000 approval -- and subsequent changes to how patients can access it -- make their way through the courts. </p><p><strong>NOTE: </strong>This episode was recorded in the afternoon of April 13, 2023, shortly before the <a href="https://www.npr.org/2023/04/13/1169690633/abortion-pill-ruling-supreme-court">Justice Department requested the Supreme Court to restore access to the mifepristone</a>. </p><p><strong>Related Links:</strong></p><ul> <li> <a href="https://www.healthaffairs.org/content/forefront/fda-s-liberalization-mifepristone-dispensing-securing-future-access-medical-abortion?utm_medium=podcast&amp;utm_source=this+week">FDA's Liberalization of Mifepristone Dispensing: Securing The Future Of Access To Medical Abortion</a> (<em>Health Affairs Forefront</em>)</li> <li> <a href="https://www.cnn.com/2023/04/10/health/mifepristone-drugmakers-letter/index.html">Drugmakers sign letter supporting FDA and calling for reversal of Texas judge's mifepristone ruling</a> (<em>CNN</em>)</li> <li> <a href="https://www.vanityfair.com/news/2023/04/abortion-medication-mifepristone-remain-legal-for-now-restrictions">Abortion Medication Mifepristone Will Remain Legal for Now, but With More Restrictions</a> (<em>Vanity Fair</em>)</li> <li><a href="https://www.justice.gov/opa/pr/statement-attorney-general-merrick-b-garland-alliance-hippocratic-medicine-v-fda-appeals">United States Department of Justice Statement - April 13, 2023</a></li> </ul><p>C<em>urrently, more than 70 percent of our content is freely available — and we’d like to keep it that way. </em><a href="https://www.healthaffairs.org/subscribe/individual?utm_medium=podcast&amp;utm_source=this+week&amp;utm_campaign=individual+subscriptions"><em>With your support,</em></a> <em>we can continue to keep our digital publication Forefront</em> <em>and podcasts free for everyone.</em></p>